Patients and others will be able to offer comments on the first group of drugs subject to Medicare price negotiations during a series of listening sessions that seem similar to the US Food and Drug Administration’s Patient-Focused Drug Development program.
The US Centers for Medicare and Medicaid Services on 29 August announced the 10 drugs that will be subject to...








